Abstract:Background: Treatment of urethral trauma is currently done after urethral stricture occurs. Stricture therapy after occurrence gives unsatisfactory success rates. Several genes, such as transforming growth factor beta 1 (TGF-β1), matrix metalloproteinase 1 (MMP-1), connective tissue growth factor (CTGF), and plasminogen activator inhibitor 1 (PAI-1), have a proven role in urethral stricture development. The purpose of this study was to assess the effect docetaxel and/or captopril on the RNA expression of those genes. Methods: The subjects of this research were 26 male New Zealand rabbits aged 230 ± 20 days weighing 4–5 kg that underwent urethral rupture by endoscopic resection under anesthetized conditions. Subjects were divided into five groups; control, stricture, captopril (captopril 0.05 mg/rabbit/day), docetaxel (docetaxel 0.1 mg/rabbit/day), and docetaxel-captopril (docetaxel 0.1 mg/rabbit/day and captopril 0.05 mg/rabbit/day). Each group consisted of 4–6 rabbits. Each rabbit received a water-soluble transurethral gel containing drug according to its group for 28 days. After the treatment period, rabbits were sacrificed with 200 mg Pentothal, and the corpus spongiosum was then prepared for real-time PCR examination. Results: TGF-β1 RNA expression in the stricture group was statistically different from that in the control, docetaxel and docetaxel-captopril groups ( p = 0.016; p = 0.016; p = 0.004). The stricture group did not exhibit any statistical difference from the captopril group ( p = 0.190). The control group did not show any statistically difference from the captopril, docetaxel, and docetaxel-captopril groups ( p = 0.114; p = 0.190; p = 1.000). Docetaxel-captopril suppresses expression of TGF-β1 RNA most significantly. MMP-1 RNA expression showed no significant differences among groups ( p = 0.827). The docetaxel group and stricture group pair was most significant ( p = 0.247), compared with other pairs of stricture groups in MMP-1 RNA expression. CTGF RNA expression in the stricture group was statistically different from that of control, captopril, docetaxel, and docetaxel-captopril groups ( p = 0.003; p = 0.019; p = 0.005; p = 0.005). The control group did not exhibit any statistically difference from the captopril, docetaxel, and docetaxel-captopril groups ( p = 0.408; p = 0.709; p = 0.695). There was no statistical difference among treatment groups. Docetaxel and docetaxel-captopril groups suppress the most significant expression of CTGF RNA expression. PAI-1 RNA expression in the stricture group differed statistically significantly from the control and docetaxel groups ( p = 0.044; p = 0.016). The stricture group did not show any statistically significant difference from the captopril and docetaxel-captopril groups ( p = 0.763; p = 0.086). The control group did not exhibit any statistical difference with any of the treatment groups ( p = 0.101; p = 0.637; p = 0.669). Conclusion: Docetaxel-captopril gel proved to be able to inhibit RNA expression of TGF-β1 and CTGF significantly. Captopril gel proved to be able to inhibit RNA expression of CTGF significantly. Docetaxel gel proved to be able to inhibit RNA expression of TGF-β1, CTGF, and PAI-1 significantly. There were no differences in MMP-1 expression among all study groups. Longer follow up after therapy discontinuation and greater sample size is needed to determine the therapeutic effect.

Characterization of urethral fibrosis in a rabbit model: Potential roles of Wnt-β catenin pathway and epithelial to mesenchymal transition

Construction of a ureteral injury animal model complicating ureteral stenosis in New Zealand rabbit

Development and Characterization of Urethral Stricture Model in Rabbits

Urethral Reconstruction with RNA Interference and Polycaprolactone/Silk Fibroin/Collagen Electrospun Fiber in Rabbits

Biodegradable Urethral Stent in the Treatment of Post-Traumatic Urethral Strictures in a War Wound Rabbit Urethral Model

Establishment of urethral stricture in rabbit model with visual endoscopic urethroelectrocoagulation

Urethral reconstruction with tissue engineering and RNA interference techniques in rabbits.

Prevention of urethral fibrosis induced by transforming growth factor beta 1 using selective Wnt/β-catenin signaling inhibitors in a rat model

Urethral Reconstruction with Small Intestinal Submucosa Seeded with Oral Keratinocytes and TIMP-1 siRNA Transfected Fibroblasts in a Rabbit Model

Post-transcriptional suppression of TIMP-1 in epithelial-differentiated adipose-derived stem cells seeded bladder acellular matrix grafts reduces urethral scar formation

Characterization of a novel rabbit model of Peyronie's disease

Tubularized Urethral Replacement Using Tissue-Engineered Peritoneum-Like Tissue in a Rabbit Model

Long-term Study of Male Rabbit Urethral Mucosa Reconstruction Using Epidermal Cell

Application of Wnt Pathway Inhibitor Delivering Scaffold for Inhibiting Fibrosis in Urethra Strictures: in Vitro and in Vivo Study.

Extracellular matrix analysis of fibrosis: A step towards tissue engineering for urethral stricture disease

Reconstruction of Rabbit Urethra Using Urethral Extracellular Matrix

The Effects and Mechanisms of the Rapamycin-eluting Stent in Urethral Stricture Prevention in Rabbits

Curative Effect and Histocompatibility Evaluation of Reconstruction of Traumatic Defect of Rabbit Urethra Using Extracellular Matrix

The effects of docetaxel and/or captopril in expression of TGF-β1, MMP-1, CTGF, and PAI-1 as markers of anterior urethral stricture in an animal model

Preliminary Experimental Study of Urethral Reconstruction with Tissue Engineering and RNA Interference Techniques

An Experimental Model of Anterior Urethral Stricture in Rabbits With Local Injections of Bleomycin